Dual and Triple Gut Peptide Agonists: The Next Wave of Obesity Treatments
Review of dual and triple gut peptide agonists on the horizon covers tirzepatide, retatrutide, CagriSema, and other multi-target obesity drugs approaching clinical use.
Quick Facts
What This Study Found
Review of dual and triple gut peptide agonists on the horizon covers tirzepatide, retatrutide, CagriSema, and other multi-target obesity drugs approaching clinical use.
Key Numbers
No specific numerical outcomes highlighted in abstract; review synthesizes data across multiple drug candidates and trials.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Review of dual and triple gut peptide agonists on the horizon covers tirzepatide, retatrutide, Cagri
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data.
- Published In:
- Current obesity reports, 14(1), 34 (2025)
- Authors:
- Anastasiou, Ioanna Α, Argyrakopoulou, Georgia(3), Dalamaga, Maria(5), Kokkinos, Alexander
- Database ID:
- RPEP-09939
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Review of dual and triple gut peptide agonists on the horizon covers tirzepatide, retatrutide, CagriSema, and other multi-target obesity drugs approaching clinical use.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09939APA
Anastasiou, Ioanna Α; Argyrakopoulou, Georgia; Dalamaga, Maria; Kokkinos, Alexander. (2025). Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data.. Current obesity reports, 14(1), 34. https://doi.org/10.1007/s13679-025-00623-1
MLA
Anastasiou, Ioanna Α, et al. "Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data.." Current obesity reports, 2025. https://doi.org/10.1007/s13679-025-00623-1
RethinkPeptides
RethinkPeptides Research Database. "Dual and Triple Gut Peptide Agonists on the Horizon for the ..." RPEP-09939. Retrieved from https://rethinkpeptides.com/research/anastasiou-2025-dual-and-triple-gut
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.